Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05137600
Other study ID # ANTT103
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 28, 2021
Est. completion date January 23, 2022

Study information

Verified date February 2022
Source Antios Therapeutics, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a single-center, open-label, 2-cohort, fixed-sequence, DDI study in healthy adult subjects. Healthy volunteers will be administered multiple oral doses of ATI-2173 in combination with midazolam or clarithromycin and assessed for safety and tolerability including blood tests to show how the body metabolizes and eliminates the investigational drug as well as how the investigational drug interacts with midazolam or clarithromycin.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date January 23, 2022
Est. primary completion date December 23, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Provision of signed and dated Informed Consent Form (ICF) 2. Stated willingness to comply with all study procedures (including ability and willingness to abstain from alcohol from 48 hours prior to the first study drug administration until discharge) and availability for the duration of the study 3. Healthy adult male or female 4. Aged between 18 and 60 years, inclusive 5. Body mass index (BMI) within 18.5 kg/m2 to 30.0 kg/m2, inclusively 6. Non- or ex-smoker (an ex-smoker is defined as someone who completely stopped using nicotine products for at least 180 days prior to the first study drug administration) 7. Suitable veins for cannulation or repeated venipuncture as assessed by an Investigator at Screening 8. If female, meets one of the following criteria: 1. Is of childbearing potential and agrees to use an acceptable contraceptive method. Acceptable contraceptive methods include - Abstinence from heterosexual intercourse from the first study drug administration through to at least 60 days after the last dose of the study drug - Non-hormonal intrauterine device (IUD) with a barrier method (eg, male condom) used from at least 28 days prior to the first study drug administration through to at least 60 days after the last dose of the study drug - Double-barrier method (eg, male condom, spermicide and diaphragm or cervical cap used simultaneously )from Screening through to at least 60 days after the last dose of the study drug - Male partner vasectomized at least 6 months prior to Screening Or 2. Is of non-childbearing potential, defined as surgically sterile (ie, has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or is in a postmenopausal state (ie, at least 1 year without menses without an alternative medical condition prior to the first study drug administration), as confirmed by follicle-stimulating hormone levels (= 40 mIU/mL). 9. If male, meets one of the following criteria: 1. Is able to procreate and agrees to use one of the accepted contraceptive regimens and not to donate sperm from the first study drug administration to at least 90 days after the last drug administration. An acceptable method of contraception includes one of the following: - Abstinence from heterosexual intercourse - Male condom with spermicide or male condom with a vaginal spermicide (gel, foam, or suppository) Or 2. Is unable to procreate; defined as surgically sterile (ie, has undergone a vasectomy at least 6 months prior to Screening) 10. Agrees to abstain from blood or plasma donation from the Screening visit until 3 months after the last study drug administration 11. Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on the physical examination, vital signs, myopathy questionnaire, and/or ECG, as determined by an Investigator Cohort 1 only 12. Have no clinically significant findings on the neurological examination and/or oxygen saturation measurement as determined by an Investigator Exclusion Criteria: 1. Female who is lactating 2. Female who is pregnant according to the pregnancy test at Screening or prior to the first study drug administration 3. Female using the following systemic contraceptives: oral, patch or vaginal ring, in the 28 days prior to the first study drug administration 4. Female using hormone replacement therapy in the 28 days prior to the first study drug administration 5. Female using the following systemic contraceptives: injections or implant, or hormone-releasing IUD in the 13 weeks prior to the first study drug administration 6. Seated pulse rate less than 50 beats per minute or more than 100 beats per minute at Screening or prior to the first study drug administration 7. Seated blood pressure below 105/60 mmHg or higher than 140/90 mmHg at Screening or prior to the first study drug administration 8. Estimated glomerular filtration rate (eGFR) = 60 mL/min/1.73m2, calculated using the Modification of Diet in Renal Disease (MDRD) equation, at Screening or prior to the first study drug administration 9. Presence of out-of-range cardiac interval (PR < 110 msec, PR > 200 msec, QRS < 60 msec, QRS >110 msec and QTcF > 440 msec) on the ECG at Screening or at Check-in or other clinically significant ECG abnormalities, unless deemed non-significant by an Investigator 10. Hemoglobin value below the lower limit of the reference laboratory at Screening or prior to study drug administration 11. Any other clinically significant abnormalities in laboratory test results at Screening. Subjects with alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), creatine kinase (CK) or total bilirubin outside the normal range at Screening or Day -1 will be excluded. 12. Positive test result for alcohol and/or drugs of abuse at Screening or prior to the first drug administration 13. Positive screening results to HIV Ag/Ab combo, hepatitis B surface antigen or hepatitis C virus antibody tests at Screening 14. Positive screening results to SARS-CoV-2 virus tests prior to the first study drug administration 15. History of significant hypersensitivity to ATI-2173, clevudine, midazolam, clarithromycin, or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs 16. Presence or history of significant gastrointestinal, liver or kidney disease, or surgery that may affect drug bioavailability 17. History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease 18. Presence of clinically significant muscle disorders, myopathies or other forms of liver disease 19. Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic) 20. Any clinically significant illness in the 28 days prior to the first study drug administration 21. Use of any prescription drugs (including hormonal contraceptives and hormone replacement therapy) or any CYP3A inhibitors, inducers, or substrates in the 30 days prior to the first study drug administration, that in the opinion of an Investigator would put into question the status of the participant as healthy 22. Use of St. John's wort in the 30 days prior to the first study drug administration 23. Use of over-the-counter (OTC) medications, herbal supplements, and vitamins in the 14 days prior to the first study treatment administration. 24. Use of quinine-containing products (eg, tonic water), grapefruit products, pomelo products, Seville orange products, including supplements containing Citrus aurantium or "bitter orange", in the 14 days prior to the first study drug administration 25. Consumption of food or beverages containing xanthines (ie, tea, coffee, cola drinks, energy drinks or chocolate) in the 48 hours prior to the first study drug administration 26. Any history of tuberculosis 27. Immunization with a coronaviruse disease 2019 (COVID-19) vaccine in the 14 days prior to the first study drug administration 28. Scheduled immunization with a COVID-19 vaccine (first or second dose) during the study that, in the opinion of an Investigator, could potentially interfere with subject participation, subject safety, study results, or any other reason 29. Inclusion in a previous group for this clinical study 30. Participation in another clinical study with a non-biologic investigational product (IP) or new formulation of a marketed non-biologic drug in the 30 days prior to Screening 31. Participation in another clinical study with any marketed or investigational biologic product within 90 days or 5 half-lives, whichever is longer, prior to Screening 32. Donation of 50 mL or more of blood in the 28 days prior to the first study drug administration 33. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the 56 days prior to the first study drug administration Cohort 1 34. Oxygen saturation (SpO2) below 95% at Screening or prior to the first study drug administration 35. Family history of sudden cardiac death or known prolonged QTc

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ATI-2173
ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
Midazolam
Midazolam is a sensitive CYP3A index substrate
Clarithromycin
Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites(clarithromycin)

Locations

Country Name City State
Canada Altasciences Montréal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Antios Therapeutics, Inc

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Cmax of 1-hydroxymidazolam Through end of study, approximately 3 months
Other AUC0-t of 1-hydroxymidazolam Through end of study, approximately 3 months
Other AUC0-inf of 1-hydroxymidazolam Through end of study, approximately 3 months
Other Ratio of metabolite to parent (midazolam) for AUC0-t Through end of study, approximately 3 months
Other Ratio of metabolite to parent (ATI-2173) for AUC0-t Through end of study, approximately 3 months
Other Ratio of metabolite to parent (ATI-2173) for AUCtau Through end of study, approximately 3 months
Other Cmax of M1 Through end of study, approximately 3 months
Other AUC0-t of M1 Through end of study, approximately 3 months
Other AUC0-inf of M1 Through end of study, approximately 3 months
Other Cmax of clevudine Through end of study, approximately 3 months
Other AUCtau of clevudine Through end of study, approximately 3 months
Primary Cmax of Midazolam Through end of study, approximately 3 months
Primary AUC0-t of Midazolam Through end of study, approximately 3 months
Primary AUC0-inf of Midazolam Through end of study, approximately 3 months
Primary Cmax of ATI-2173 Through end of study, approximately 3 months
Primary AUCtau of ATI-2173 Through end of study, approximately 3 months
Primary AUC0-t of ATI-2173 Through end of study, approximately 3 months
Primary AUCo-inf of ATI-2173 Through end of study, approximately 3 months
Secondary Number of adverse events Through end of study, approximately 3 months
See also
  Status Clinical Trial Phase
Completed NCT05574374 - Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects Phase 1
Completed NCT04557397 - Fruquintinib CYP3A Inhibitor and Inducer Study Phase 1
Completed NCT06031454 - Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin Phase 1
Recruiting NCT06119958 - Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects Phase 1
Active, not recruiting NCT05812404 - Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects Phase 1
Completed NCT04606537 - Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects Phase 1
Completed NCT04939467 - Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Completed NCT04542252 - Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects Phase 1
Enrolling by invitation NCT06037564 - B-free Multistage Trial Phase 4
Completed NCT05123820 - Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470 Phase 1
Recruiting NCT04840862 - Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor Phase 4
Completed NCT04814498 - Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Completed NCT01350921 - Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers Phase 1
Completed NCT03103568 - A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers Phase 1
Completed NCT04840641 - Flucloxacillin as an Inducer of CYP-enzymes Phase 1
Completed NCT05860114 - Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3) Phase 1
Completed NCT05304845 - Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects Phase 1
Completed NCT05845567 - The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2) Phase 1
Completed NCT04776499 - Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers Phase 1
Completed NCT03909529 - Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug) Phase 1